DOCSLIB.ORG

Noninfectious Uveitis Open Access to Scientific and Medical Research DOI

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Noninfectious Uveitis Open Access to Scientific and Medical Research DOI Journal name: Clinical Ophthalmology Article Designation: Review Year: 2015 Volume: 9 Clinical Ophthalmology Dovepress Running head verso: Dolz-Marco et al Running head recto: Compliance and adherence in noninfectious uveitis open access to scientific and medical research DOI: http://dx.doi.org/10.2147/OPTH.S36650 Open Access Full Text Article REVIEW Noninfectious uveitis: strategies to optimize treatment compliance and adherence Rosa Dolz-Marco1 Abstract: Noninfectious uveitis includes a heterogenous group of sight-threatening ocular Roberto Gallego-Pinazo1 and systemic disorders. Significant progress has been made in the treatment of noninfectious Manuel Díaz-Llopis2 uveitis in recent years, particularly with regard to the effective use of corticosteroids and Emmett T Cunningham Jr3–6 non-corticosteroid immunosuppressive drugs, including biologic agents. All of these therapeutic J Fernando Arévalo7,8 approaches are limited, however, by any given patient’s ability to comply with and adhere to their prescribed treatment. In fact, compliance and adherence are among the most important 1Unit of Macula, Department of patient-related determinants of treatment success. We discuss strategies to optimize compliance Ophthalmology, University and Polytechnic Hospital La Fe, 2Faculty and adherence. of Medicine, University of Valencia, Keywords: noninfectious uveitis, intraocular inflammation, immunosuppressive treatment, Spain; 3Department of Ophthalmology, California Pacific Medical Center, adherence, compliance, therapeutic failure San Francisco, 4Department of Ophthalmology, Stanford University For personal use only. School of Medicine, Stanford, 5The Introduction Francis I Proctor Foundation, Noninfectious uveitis includes a heterogenous group of sight-threatening University of California San Francisco 1,2 Medical Center, 6West Coast Retina immune-mediated ocular and systemic disorders. In some conditions, the inflam- Medical Group, San Francisco, CA, mation is limited to the eye (primary ocular uveitis), whereas in other conditions, the USA; 7Vitreoretina Division, King 3–5 Khaled Eye Specialist Hospital, uveitis is but one manifestation of a more complex systemic condition. Noninfec- Riyadh, Saudi Arabia; 8Retina Division, tious uveitis may present at any age, but occurs most frequently in patients between Wilmer Eye Institute, Johns Hopkins 3–5 University School of Medicine, 20 and 50 years of age. Uveitis may be either acute or chronic, and within these two Baltimore, MD, USA broad categories, the course, duration, and severity can vary markedly.6 Therefore, treatment approaches needs to be tailored, to individual patients.6 The emergence of complicated, multidrug therapies for the management of intraocular inflamma- Clinical Ophthalmology downloaded from https://www.dovepress.com/ by 54.191.40.80 on 17-Jun-2017 tion requires that patients play a major role in treatment selection to ensure success. Treatment compliance and adherence, in particular, are among the most important patient-related determinants of treatment success.7 In order to discuss compliance and adherence, a clear and acceptable definition should be established. Although both terms are widely used as synonymous, they are not equivalent. In health care, treatment compliance is a “physician-centered” term, describing the degree to which patients properly follow the instructions or recommen- dations provided by their health care providers.8 Treatment adherence is a “patient- centered” term, referring to the extent to which a patient continues the agreed-upon mode of treatment under limited supervision when faced with conflicting demands.8 Correspondence: J Fernando Arévalo Use of either binary (noncompliance or compliance; non-adherence or adherence) or The Wilmer Eye Institute, Johns Hopkins somewhat vague (good, poor, limited, etc) terms to describe patient compliance and University School of Medicine, 600 N. adherence is commonplace.9,10 Wolfe Street, Maumenee 708, Baltimore, MD 21287, USA The purpose of the present review is to summarize the currently available methods Tel +1 443 287 9554 for optimizing immunosuppressive treatment adherence in patients with noninfectious Fax +1 443 287 5492 Email [email protected] posterior uveitis. submit your manuscript | www.dovepress.com Clinical Ophthalmology 2015:9 1477–1481 1477 Dovepress © 2015 Dolz-Marco et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further http://dx.doi.org/10.2147/OPTH.S36650 permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Powered by TCPDF (www.tcpdf.org) 1 / 1 Dolz-Marco et al Dovepress Summary of therapeutic options Understandably, the views and responses of caregivers to for noninfectious uveitis these various issues have a major influence on outcomes.21–24 Relevant advances in the treatment of noninfectious uveitis While addressing patient compliance and adherence, it is have taken place within the last decade.11 Although “classic” important for the caregiver to distinguish intentional non- immunosuppressive drugs are still used most often, newer compliance, based typically on fear or misconception, from agents have been added to existing therapies.6,12,13 Table 1 unintentional noncompliance, which usually reflects a lack summarizes both existing and emerging treatments for the of understanding, busyness, or forgetfulness.25 For instance, a management of noninfectious uveitis. young patient might be reluctant to have oral steroids as these are associated with weight increase (intentional noncompli- Causes of compliance and adherence ance); on the other hand, a patient might forget to have the failure medication when symptoms are improving (unintentional Noncompliance and non-adherence are complex and mul- noncompliance). tidimensional health care issues. The World Health Orga- nization classifies the risk factors for noncompliance and Measuring treatment compliance and non-adherence into socioeconomic, patient-related, condi- adherence tion/disease-related, therapy/treatment-related, and health Noninfectious uveitis may occur as an isolated episode, or care system/worker-related risk factors.14 more frequently, as either chronic or recurrent disease.26 Socioeconomic factors have been studied across medi- Although patients presenting with a single episode are typi- cal disciplines and can be related to either the patient or cally compliant and adherent to prescribed treatments, both the caregiver.15–20 Patient-related socioeconomic factors compliance and adherence are more difficult to achieve over can result in poor understanding of the disease or its treat- time. While there is no gold-standard method for monitoring ment, in support of belief in unvalidated, belief-based treat- compliance and adherence to immunosuppressive therapies, several approaches are available including patient self-report, For personal use only. ment approaches, and limited access to care or treatment. pill counting, refill rates, biological monitoring, and elec- 27–29 Table 1 Immunosuppressive drugs for the management of tronic monitoring. These approaches, like many others, noninfectious Uveitis are not ideal in routine clinical practice, because they have Existing treatments Corticosteroids relevant limitations. Leukocyte signaling Cyclosporine A inhibitors Tacrolimus Plasma levels Antimetabolites Azathioprine Direct measurement of plasma drug levels is a widely Methotrexate available technique used for cyclosporine, tacrolimus, Mycophenolate 27–29 (mofetil and sodium) mycophenolate, and everolimus. Such pharmacokinetic Clinical Ophthalmology downloaded from https://www.dovepress.com/ by 54.191.40.80 on 17-Jun-2017 Alkylating agents Cyclophosphamide monitoring is a reliable, albeit somewhat costly and cum- Chlorambucil bersome means of evaluating compliance and adherence Tumor necrosis Etanercept to these treatments. factor-alpha inhibitors Infliximab Adalimumab Golimumab Medication counting Certolizumab Both the uveitis specialist and the pharmacist can monitor Emerging treatments Abatacept adherence to treatment by counting pills or prescription Alemtuzumab refills, or by administering questionnaires to measure self- Anakinra Brodalumab reported adherence. A medication diary or monitoring is Efalizumab another possibility, such as the “corticosteroid treatment Fezakinumab card” currently recommended for patients prescribed sys- Gevokizumab temic corticosteroids for more than 3 weeks in the UK.27–29 Ixekizumab Rituximab This particular strategy gives guidance to patients on Secukinumab minimizing adverse events and also provides data from the Tocilizumab prescribing physician, characteristics of the drug as well as Ustekinumab dosage and treatment duration. 1478 submit your manuscript | www.dovepress.com Clinical Ophthalmology 2015:9 Dovepress Powered by TCPDF (www.tcpdf.org) 1 / 1 Dovepress Compliance and adherence in noninfectious uveitis Route of administration Table 2 Summary of the main adverse effects of the most Optimizing the route of administration is helpful in order frequently used existing immunosuppressive agents for
Load more

Recommended publications
  • Old and New Challenges in Uveitis Associated with Behçet's Disease
    Journal of Clinical Medicine Review Old and New Challenges in Uveitis Associated with Behçet’s Disease Julie Gueudry 1,* , Mathilde Leclercq 2, David Saadoun 3,4,5 and Bahram Bodaghi 6 1 Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France 2 Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France; [email protected] 3 Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de Références Maladies Autoimmunes et Systémiques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] 4 Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France 5 Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, AP-HP, F-75651 Paris, France 6 Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-2-32-88-80-57 Abstract: Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage.
    [Show full text]
  • Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
    Review Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease A. Arida, P.P. Sfikakis First Department of Propedeutic Internal ABSTRACT and thrombotic complications (1-3). Medicine Laikon Hospital, Athens, Unmet therapeutic needs in Behçet’s Treatment varies according to type and University Medical School, Greece. disease have drawn recent attention to severity of disease manifestations. Cor- Aikaterini Arida, MD biological agents targeting cytokines ticosteroids, interferon-alpha and con- Petros P. Sfikakis, MD other than TNF. The anti-IL-17 anti- ventional immunosuppressive drugs, Please address correspondence to: body secukinumab and the anti-IL-2 such as azathioprine, cyclosporine-A, Petros P. Sfikakis, MD, receptor antibody daclizumab were not cyclophosphamide and methotrexate, First Department of Propedeutic superior to placebo for ocular Behçet’s and Internal Medicine, are used either alone or in combination Laikon Hospital, in randomised controlled trials, com- for vital organ involvement. During the Athens University Medical School, prising 118 and 17 patients, respec- last decade there has been increased use Ag Thoma, 17, tively. The anti-IL-1 agents anakinra of anti-TNF monoclonal antibodies in GR-11527 Athens, Greece. and canakinumab and the anti-IL-6 patients with BD who were refractory E-mail: [email protected] agent tocilizumab were given to iso- to conventional treatment or developed Received on June 7, 2014; accepted in lated refractory disease patients, who life-threatening complications (4, 5). revised form on September 17, 2014. were either anti-TNF naïve (n=9) or Anti-TNF treatment has been shown to Clin Exp Rheumatol 2014; 32 (Suppl. 84): experienced (n=18).
    [Show full text]
  • New Biological Therapies: Introduction to the Basis of the Risk of Infection
    New biological therapies: introduction to the basis of the risk of infection Mario FERNÁNDEZ RUIZ, MD, PhD Unit of Infectious Diseases Hospital Universitario “12 de Octubre”, Madrid ESCMIDInstituto de Investigación eLibraryHospital “12 de Octubre” (i+12) © by author Transparency Declaration Over the last 24 months I have received honoraria for talks on behalf of • Astellas Pharma • Gillead Sciences • Roche • Sanofi • Qiagen Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Paul Ehrlich (1854-1915) • “side-chain” theory (1897) • receptor-ligand concept (1900) • “magic bullet” theory • foundation for specific chemotherapy (1906) • Nobel Prize in Physiology and Medicine (1908) (together with Metchnikoff) Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author 1981: B-1 antibody (tositumomab) anti-CD20 monoclonal antibody 1997: FDA approval of rituximab for the treatment of relapsed or refractory CD20-positive NHL 2001: FDA approval of imatinib for the treatment of chronic myelogenous leukemia Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Functional classification of targeted (biological) agents • Agents targeting soluble immune effector molecules • Agents targeting cell surface receptors
    [Show full text]
  • Clinical Research in Adult Vasculitis
    Clinical research in adult vasculitis Calgary – October 8th, 2015 Disclosures • Consulting and speaker fees – Hoffmann-La Roche – BMS • Advisory boards – Hoffmann-La Roche – GSK • Educational subventions (CanVasc) – Hoffmann-La Roche – Terumo BCT – Abbott Immunology – BMS – Pfizer-Amgen – Janssen-Cilag – Euroimmun Learning Outcomes 1. To review some of the existing international research networks and groups 2. To review some of the ongoing studies on adult vasculitis, in which Canada participates 3. To discuss issues pertinent to various specialties (internal medicine, rheumatology, nephrology and respirology) including research collaboration in Canada 4. To be aware of CanVasc and its activities in adult vasculitis 2012 revised Chapel hill nomenclature Jennette et al. Arthritis Rheum. 2013 Treatment of severe GPA/MPA CYCLOPHOSPHAMIDE AZATHIOPRINE 2 mg/kg/d 15 mg/kg (d1,14,28 then q3wk) METHOTREXATE 0.3 mg/kg/wk ? LEFLUNOMIDE 20 mg/d 2 mg/kg/d MYCOPHENOLATE MOFETIL 2 g/d Rituximab 500mg q6m RITUXIMAB 375mg/m2 x4 ? + Corticosteroids R 3 - 6 months > 18 months INDUCTION MAINTENANCE + adjuvant/prophylactic measures: cotrimoxazole, osteoporosis treatment, etc DCVAS Study – ACR/EULAR diagnostic and classification criteria for vasculitis – Number of centres: 118 This project anticipates to produce the following: • 1) A new validated set of classification criteria for the primary systemic vasculitides. • 2) A validated set of diagnostic criteria for the primary systemic vasculitides. DCVAS Study • How will the final revisions differ from the current ACR criteria? • The main differences will be: • Use modern diagnostic tests (e.g. ANCA, use of diagnostic ultrasound for GCA), new tools of disease activity (BVAS) and tools measuring vasculitis damage (VDI) to further refine the criteria.
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]
  • An Update on the Use of Biologic Therapies in the Management of Uveitis in Behçet’S Disease: a Comprehensive Review Thomas W
    McNally et al. Orphanet Journal of Rare Diseases (2017) 12:130 DOI 10.1186/s13023-017-0681-6 REVIEW Open Access An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review Thomas W. McNally1, Erika M. Damato2,3, Philip I. Murray2,3,4,5, Alastair K. Denniston4,5,6* and Robert J. Barry4,5 Abstract Behçet’s disease (BD) is a systemic vasculitis characterised by a relapsing remitting course, affecting multiple organ systems. In the eye, it is a cause of potentially blinding inflammation in the form of uveitis. Management of uveitis in BD often requires the use of systemic immunosuppression, in order to reduce disease activity and prevent accumulation of irreversible damage. Whilst corticosteroids remain the mainstay of treatment, long-term use is limited by the development of adrenocorticotrophic side effects. There has therefore been significant interest in the use of corticosteroid-sparing immunosuppressive agents, and more recently, biologic therapies. Recent publications have demonstrated biologic therapy to have beneficial effects both on overall disease control, and quality of life for patients with BD. Widespread use of such agents is however limited, partly by the lack of high quality research evidence, and partly by the prohibitive cost of biologic treatments. In this review, we discuss the most recent research investigating the use of biologic therapy in uveitis due to BD, with consideration of health economics and quality of life outcomes. Keywords: Behçet’s disease, Biologic therapy, Health economics, Immunosuppression, Quality of life, Steroid-sparing agents, Uveitis Background BD occurs throughout all geographic locations, being Behçet’s disease (BD) is a multi-system inflammatory most prevalent and often more severe in countries dis- disorder of unknown aetiology [1, 2].
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • Gevokizumab for Chronic Non-Infectious Uveitis
    Horizon Scanning Centre July 2013 Gevokizumab for chronic non- infectious uveitis SUMMARY NIHR HSC ID: 8064 Gevokizumab is an anti-inflammatory humanised IgG2 monoclonal antibody that binds to interleukin-1ß (IL-1ß). It is intended for treatment of chronic, non-infectious uveitis, including that associated with Behҫet’s disease. Binding to IL-1ß blocks the activation of the IL-1 receptor preventing cellular signalling events that produce inflammation. Gevokizumab is intended for monthly subcutaneous (SC) dosing. Uveitis is inflammation of the uveal tract of the eye, which consists of the iris, This briefing is the ciliary body and the choroid. Inflammation of nearby tissues, such as the based on retina, the optic nerve, and the vitreous humour may also occur. Uveitis may information be classified by the anatomical location of the pathology: anterior, available at the time intermediate (vitritis), posterior (retina and choroid) or panuveitis. Chronic of research and a uveitis may be defined as active uveitis that persists longer than three limited literature months. Symptoms of uveitis include: pain, redness, photophobia, search. It is not headaches, visual floaters and decreased visual acuity. Non-infectious intended to be a uveitis may be due to an underlying inflammatory condition, an autoimmune definitive statement disorder or occur as a result of trauma to the eye. In many cases the cause on the safety, remains uncertain. Systemic diseases such as Behҫet’s disease and efficacy or sarcoidosis can be associated with either acute or chronic uveitis. Ocular effectiveness of the involvement is common in Behçet’s disease, and may cause severe uveitis. health technology covered and should The overall incidence of uveitis is estimated to be between 17 and 52.4 per not be used for 100,000 population equating to between 9,500 and 29,200 new cases per commercial year in the UK.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • WO 2018/234879 Al 27 December 2018 (27.12.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/234879 Al 27 December 2018 (27.12.2018) W !P O PCT (51) International Patent Classification: c/o Novartis Pharmaceuticals Corporation, One Health C07K 16/24 (2006.01) A61K 39/00 (2006.01) Plaza, East Hanover, New Jersey 07936 (US). THUREN, Tom; c/o Novartis Pharmaceuticals Corporation, One (21) International Application Number: Health Plaza, East Hanover, New Jersey 07936 (US). R - PCT/IB20 18/053096 KER, Paul; c/o The Brigham and Women's Hospital, 75 (22) International Filing Date: Francis Street, Boston, Massachusetts 021 15 (US). LIB- 03 May 2018 (03.05.2018) BY, Peter; c/o The Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 021 15 (US). OT- (25) Filing Language: English TEWELL, Penelope; c/o The Medical School, Beech Hill (26) Publication Langi English Road, Sheffield South Yorkshire S10 2RX (GB). LAU, Yi Yang; c/o Novartis Pharmaceuticals Corporation, One (30) Priority Data: Health Plaza, East Hanover, New Jersey 07936 (US). 62/523,458 22 June 2017 (22.06.2017) US DUGAN, Margaret; c/o Novartis Pharmaceuticals Corpo 62/529,5 15 07 July 2017 (07.07.2017) US ration, One Health Plaza, East Hanover, New Jersey 07936 62/550,307 25 August 2017 (25.08.2017) US (US). 62/550,325 25 August 2017 (25.08.2017) US 62/596,054 07 December 20 17 (07. 12.20 17) US (81) Designated States (unless otherwise indicated, for every 62/649,63 1 29 March 2018 (29.03.2018) US kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 4056 Basel (CH).
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]